-
LABORATORY-BASED MACHINE LEARNING ALGORITHM REDUCES UNCERTAINTY AND ENHANCES DIAGNOSTIC ACCURACY IN PERIPROSTHETIC JOINT INFECTION
Mar 18, 2026, 21:38 PM -
PREVALENCE RATES OF MYOTONIC DYSTROPHY TYPE 1 (DM1) IN 9 COUNTRIES: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
Mar 18, 2026, 21:38 PM -
DIRECT ORAL ANTICOAGULANTS IN BRAZIL: PRICE TRENDS, MARKET COMPETITION, AND POLICY IMPLICATIONS
Mar 18, 2026, 21:38 PM -
REAL-WORLD CHARACTERISTICS AND HEALTHCARE RESOURCE USE IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB IN SWEDEN: THE BIMENORDIX STUDY
Mar 18, 2026, 21:38 PM -
INCLUSION OF PATIENT-REPORTED OUTCOME MEASURES FOR PEDIATRIC VERSUS ADULT POPULATIONS IN FDA BIOLOGICAL AND NOVEL DRUG THERAPY APPROVALS FROM 2021-2025
Mar 18, 2026, 21:38 PM -
PRESERVING VISION AND PRODUCTIVITY: THE SOCIAL IMPACT OF INNOVATIVE DME THERAPY IN CHILE
Mar 18, 2026, 21:38 PM -
UTILIZATION, EXPENDITURE, AND PRICE TRENDS FOR EZETIMIBE AND NOVEL LIPID-LOWERING MEDICATIONS IN U.S. MEDICAID DRUG UTILIZATION DATA, 2002-2024
Mar 18, 2026, 21:38 PM -
ECONOMIC BURDEN OF DIAGNOSED METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN US ADULTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY
Mar 18, 2026, 21:38 PM -
ECONOMIC EVALUATION OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN PRETERM INFANTS IN ECUADOR
Mar 18, 2026, 21:38 PM -
CLINICIAN TESTING OF A PREFERENCE-BASED MEASURE TO TEST SENSITIVITY AND RELEVANCE FOR UTILITIES ESTIMATION IN EARLY HD
Mar 18, 2026, 21:38 PM -
DISEASE BURDEN OF DIABETIC KIDNEY DISEASE IN CHINA: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST OF CARE FOR ELDERLY HF PATIENTS WHO ADD EMPAGLIFLOZIN TO TREATMENT REGIMEN
Mar 18, 2026, 21:38 PM -
THE IMPACT OF GENERALIZED RISK ADJUSTED COST-EFFECTIVENESS ANALYSIS (GRACE) ON VALUE ASSESSMENT: FROM FORMAL ADOPTION TO GLOBAL METHODOLOGICAL TRENDS
Mar 18, 2026, 21:38 PM -
COST ANALYSIS OF LUPUS NEPHRITIS IN THE BRAZILIAN UNIFIED HEALTH SYSTEM - RWD STUDY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS FOR CARDIOVASCULAR PROTECTION AMONG U.S. ADULTS WITH DIABETES: A MEPS-BASED ECONOMIC EVALUATION 2022
Mar 18, 2026, 21:38 PM -
US PAYER CURRENT AND FUTURE ADOPTION OF ARTIFICIAL INTELLIGENCE
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH EGFR-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
SOCIAL AND STRUCTURAL DETERMINANTS OF BUPRENORPHINE ADHERENCE AMONG INDIVIDUALS WITH OPIOID USE DISORDER
Mar 18, 2026, 21:38 PM -
THE COST OF INEQUITY: ESTIMATING THE IMPACT OF DELAYED ACCESS TO NEOADJUVANT PERTUZUMAB IN CANADA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF AMIVANTAMAB PLUS LAZERTINIB FOR FIRST-LINE TREATMENT OF EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER: A U.S. PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM
